SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum Architecture
The benchmark produced the same qualifying gene-triplet results faster, but did not establish their clinical validity or predictive value.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SciSparc (SPRC) announced that CliniQuantum, its subsidiary NeuroThera Labs’ majority-owned subsidiary, completed a biomedical computing benchmark with approximately 16.8-fold acceleration.
The evaluation used gene-expression data from 11 patients and 3,531 features. Searching 7,331,162,245 possible three-gene combinations identified approximately 22.2 million triplets meeting a predefined correlation threshold. Processing took approximately 0.5 hours with GPU acceleration versus 8.4 hours using 64 virtual CPUs, producing the same qualifying results. The benchmark used IBM Qiskit Aer quantum simulation on an AWS machine, rather than execution on quantum computing hardware.
The test did not establish clinical validity, predictive value or utility. CliniQuantum plans to analyze more complex configurations and larger biomedical datasets while advancing toward quantum-hardware execution.
Positive
- Minor pointCompleted benchmark achieved approximately 16.8-fold computational acceleration versus the CPU-only implementation on the same machine.
- Minor pointGene analysis identified approximately 22.2 million correlated triplets meeting a predefined threshold.
- Minor point. Forward-looking: it has not happened yet and may not happen.Development plans target more complex configurations, larger biomedical datasets and eventual quantum-hardware execution.
Negative
- Minor pointBenchmark scope did not evaluate or establish clinical validity, predictive value or potential utility of identified combinations.
Details
Market move: SPRC +3.70% vs previous close. quantum platform benchmark
On Oct 7, the day this news came out, the latest delayed price for SPRC is 3.70% above the previous close. Argus tracked a peak move of +5.0% during the session. Argus tracked a trough of -21.4% from its starting point during tracking. Our momentum scanner has recorded 6 alerts for this stock so far that day. The latest delayed price is $4.49.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Computational acceleration
- approximately 16.8-fold
- GPU-accelerated platform versus CPU implementation
- Dataset patients
- 11 patients
- Real clinical gene-expression dataset
- Gene-expression features
- 3,531 features
- Real clinical gene-expression dataset
- Three-gene combinations
- 7,331,162,245 combinations
- Possible combinations searched by the algorithm
- Correlated gene triplets
- approximately 22.2 million
- Identified using a predefined minimum correlation threshold
- Analysis runtime
- approximately 8.4 hours vs. approximately 0.5 hours
- 64 vCPUs versus a single NVIDIA T4 GPU; same qualifying results
Previous Clinical trial Reports
-
NeuroThera reported an end-to-end quantum-classical clinical-data workflow in simulation.
-
NeuroThera reported internal validation of its quantum-sampling workflow on a hybrid platform.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
gene-expression medical
quantum simulation technical
vcpu technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
TEL AVIV, Israel, Oct. 07, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, that CliniQuantum Ltd. (“CliniQuantum”), NeuroThera’s majority owned subsidiary, reported that its Graphics Processing Unit- accelerated (“GPU”) quantum-simulation platform achieved an approximately 16.8-fold computational acceleration using a single machine with 64 cores (x86_64) and a single NVIDIA T4 Tensor Core GPU compared with the same 64-vCPU machine with only Central Processing Unit (“CPU”) implementation.
The evaluation used a real clinical gene-expression dataset comprising 11 patients and 3,531 gene-expression features, representing a challenging high-dimensional setting in which the number of biological variables greatly exceeds the number of patients.
The algorithm operated by CliniQuantum searched for correlated three-gene configurations across the dataset. The 3,531 genes generated 7,331,162,245 possible three-gene combinations. Using a predefined minimum correlation threshold, the algorithm identified approximately 22.2 million correlated gene triplets.
The analysis required approximately 8.4 hours using 64 vCPUs (virtual CPU), compared with approximately 0.5 hours when accelerated using a single NVIDIA T4 GPU, while producing the same qualifying gene-triplet results.
The benchmark was conducted on an AWS g4dn.16xlarge EC2 machine using an IBM Qiskit Aer GPU-based quantum simulation, with a NVIDIA T4 Tensor Core GPU. The benchmark was designed to evaluate computational performance and did not evaluate or establish the clinical validity, predictive value, or potential utility of any identified gene combinations.
CliniQuantum intends to continue advancing its algorithms toward the analysis of increasingly complex multi-feature configurations and larger biomedical datasets, while progressing its development pathway from simulation and validation toward execution on quantum computing hardware.
About SciSparc Ltd. (Nasdaq: SPRC):
The Company, through its majority-owned subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of autism spectrum disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.
About NeuroThera Labs Inc.
NeuroThera is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the potential benefits and advantages of CliniQuantum’s algorithm, its advancement toward the analysis of increasingly complex multi-feature configurations and larger biomedical datasets and progressing its development pathway from simulation and validation toward execution on quantum computing hardware. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, as amended, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did SciSparc’s CliniQuantum computing benchmark demonstrate?
CliniQuantum achieved approximately 16.8-fold computational acceleration with GPU-based quantum simulation compared with a CPU-only implementation on the same machine. Processing took approximately 0.5 hours with GPU acceleration versus approximately 8.4 hours using 64 virtual CPUs, with the same qualifying gene-triplet results.
Did SciSparc’s CliniQuantum benchmark validate the gene combinations for clinical use?
No. The benchmark evaluated computational performance and did not evaluate or establish the clinical validity, predictive value or potential utility of the identified gene combinations. Its dataset comprised 11 patients and 3,531 gene-expression features.
What computing hardware did CliniQuantum use for the SciSparc benchmark?
The benchmark ran on an AWS g4dn.16xlarge EC2 machine using IBM Qiskit Aer GPU-based quantum simulation and a single NVIDIA T4 Tensor Core GPU. The accelerated configuration used a single machine with 64 cores, compared with the same 64-vCPU machine running only the CPU implementation.